Back to Journals
School of Medicine, University of Aberdeen, United Kingdom
Editor-in-Chief: Professor Garry Walsh
Dr Walsh is reader in Inflammation and Immunity and principal investigator of the Asthmatic and Allergic Inflammation Group, School of Medicine and Dentistry, University of Aberdeen, UK. His group is part of the Immunology Research Programme, within the Division of Applied Medicine that was rated fourth equal in the UK in the 2008 research assessment exercise.
Dr Walsh is honorary professor of inflammation and immunity, School of Medicine, Trinity College, Dublin, Ireland. His major research interests involve elucidation of the molecular mechanisms controlling the initiation and resolution of the inflammatory processes underlying asthma, COPD and allergic disease. Dr Walsh has published over 60 peer-reviewed articles in international journals together with more than 60 invited editorials, reviews and book chapters. To date these publications have been cited over 3,300 times, giving an h-index of 33 (source ISI Web of Knowledge). Dr Walsh has been an invited speaker and/or chairman at over fifty international meetings. In addition to his role as the editor-in-chief of Therapeutics and Clinical Risk Management he is the founding editor of the Journal of Cell Death, and Clinical Medicine - Therapeutics. He is also an editorial board member of the Journal of Allergy (section head), International Journal of Biomedical Science, Biologics: targets and therapy, The Open Immunology Journal, The Open Inflammation Journal, The Open Allergy Journal and the Journal of Organ Dysfunction.
Dr Walsh is a regular reviewer for over 40 clinical and scientific journals and serves as a grant reviewer for UK and international funding bodies. Since 2003 he has been a European Commission evaluation expert for FP6 and FP7 and is currently vice-chair of the Evaluation Panel for Marie Curie Mobility Actions. Dr Walsh is a member of the MRC College of Experts affiliated to the Infection and Immunity Board and a member of Lung Cellular and Molecular Immunology (LCMI) Special Emphasis Panel, National Institutes of Health USA.
Darren M Ashcroft, Director, Centre for Pharmacoepidemiology and Drug Safety Manchester Pharmacy School University of Manchester, UK
Henry R. Black, Rush University Hypertension Center, Rush Presbyterian/St. Luke’s Medical Center, Chicago, IL, USA
Dr Di Pierro
Francesco Di Pierro, Scientific Director, Velleja Research, Pontenure, Italy
John A. Glaspy, Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
Prof. Dr. Hartzema
Abraham G. Hartzema, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
David M. Herrington, Professor of Internal Medicine-Cardiology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
Philip D. Home, Professor of Diabetes Medicine, Newcastle University, Newcastle upon Tyne, UK
Robert H. Howland, Associate Professor of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
Robert P. Navarro, Navarro Pharma, LLC, Raleigh, North Carolina, USA
Senaka Rajapakse, Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka
Olivier Rascol, Clinical Investigation Centre, Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France
Prof. Dr. Sanz
Emilio J. Sanz, University of La Laguna School of Medicine, La Laguna, Tenerife, Spain
Alberto Zanchetti, Professor, University of Milan, Milan, Italy